{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:39:29Z","timestamp":1792096769111,"version":"4.4.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"Horizon 2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["778051"],"award-info":[{"award-number":["778051"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministry of Science and Higher Education of the Republic of Poland","doi-asserted-by":"publisher","award":["3899\/H2020\/2018\/2"],"award-info":[{"award-number":["3899\/H2020\/2018\/2"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI137080"],"award-info":[{"award-number":["R01 AI137080"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jpba.2023.115650","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:38:08Z","timestamp":1692099488000},"page":"115650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["New approach to rifampicin stability and first-line anti-tubercular drug pharmacokinetics by UPLC-MS\/MS"],"prefix":"10.1016","volume":"235","author":[{"given":"Marta","family":"Kara\u017aniewicz-\u0141ada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kosicka-Noworzy\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakruti","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingda L.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Heysell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115650_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2023.115650_bib2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis","volume":"62","author":"Peloquin","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2023.115650_bib3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/17425255.2016.1162785","article-title":"Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis","volume":"12","author":"Zuur","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jpba.2023.115650_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3343\/alm.2017.37.2.97","article-title":"Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations","volume":"37","author":"Choi","year":"2017","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.jpba.2023.115650_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17425255.2021.1836158","article-title":"Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems","volume":"17","author":"M\u00e4rtson","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jpba.2023.115650_bib6","first-page":"1","article-title":"The impact of first-line anti-tubercular drugs\u2019 pharmacokinetics on treatment outcome: a systematic review","volume":"13","author":"Sileshi","year":"2021","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2023.115650_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.5588\/ijtld.15.0803","article-title":"Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis","volume":"20","author":"Mota","year":"2016","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.jpba.2023.115650_bib8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.4155\/bio-2018-0174","article-title":"Stability studies of rifampicin in plasma and urine of tuberculosis patients according to the European medicines agency guidelines","volume":"11","author":"Mishra","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2023.115650_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113941","article-title":"Evaluation of the effect of temperature on the stability and antimicrobial activity of rifampicin quinone","volume":"197","author":"Sutradhar","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115650_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e07532","article-title":"Simultaneous determination of first-line anti-tuberculosis drugs and one metabolite of isoniazid by liquid chromatography\/tandem mass spectrometry in patients with human immunodeficiency virus-tuberculosis coinfection","volume":"7","author":"Xing","year":"2021","journal-title":"Heliyon"},{"key":"10.1016\/j.jpba.2023.115650_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00007691-199712000-00011","article-title":"Stability of rifampin in plasma: consequences for therapeutic monitoring and pharmacokinetic studies","volume":"19","author":"Le Guellec","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2023.115650_bib12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00007691-199808000-00017","article-title":"Rifampin stability","volume":"20","author":"Peloquin","year":"1998","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2023.115650_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-5173(99)00286-0","article-title":"Stability of rifampicin in dissolution medium in presence of isoniazid","volume":"190","author":"Shishoo","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2023.115650_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0378-5173(01)00754-2","article-title":"A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem","volume":"228","author":"Singh","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpba.2023.115650_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clinms.2018.10.002","article-title":"Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs","volume":"14","author":"Kuhlin","year":"2019","journal-title":"Clin. Mass Spectrom."},{"key":"10.1016\/j.jpba.2023.115650_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchromb.2018.10.027","article-title":"Simultaneous quantification of four first line antitubercular drugs and metabolites in human plasma by hydrophilic interaction chromatography and tandem mass spectrometry","volume":"1105","author":"Sundell","year":"2019","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2023.115650_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2019.113076","article-title":"Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS\/MS","volume":"180","author":"Wu","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115650_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.tube.2017.11.012","article-title":"Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS\/MS: application to therapeutic drug monitoring","volume":"109","author":"Gao","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jpba.2023.115650_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/rcm.9425","article-title":"A high-throughput LC\u2013MS\/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma","volume":"37","author":"Pr\u0161o","year":"2023","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2023.115650_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122246","article-title":"Rapid and simultaneous determination of ten anti-tuberculosis drugs in human plasma by UPLC-MS\/MS with applications in therapeutic drug monitoring","volume":"1152","author":"Wang","year":"2020","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2023.115650_bib21","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/apm.12590","article-title":"Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography\/tandem mass spectrometry","volume":"124","author":"Prahl","year":"2016","journal-title":"APMIS"},{"key":"10.1016\/j.jpba.2023.115650_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/iub.321","article-title":"Determination of antituberculosis drug concentration in human plasma by MALDI-TOF\/TOF","volume":"62","author":"Notari","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jpba.2023.115650_bib23","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1093\/jac\/dkv148","article-title":"A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs","volume":"70","author":"Baietto","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2023.115650_bib24","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1007\/s00216-013-7049-0","article-title":"Development and validation of a hydrophilic interaction liquid chromatography\u2013tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma","volume":"405","author":"Zhou","year":"2013","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2023.115650_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.17145\/jab.15.015","article-title":"Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry","volume":"1","author":"Sturkenboom","year":"2015","journal-title":"J. Appl. Bioanal."},{"key":"10.1016\/j.jpba.2023.115650_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpba.2014.09.019","article-title":"Development and validation of liquid chromatography tandem mass spectrometry method for simultaneous quantification of first line tuberculosis drugs and metabolites in human plasma and its application in clinical study","volume":"102","author":"Hee","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115650_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7324\/JAPS.2018.8910","article-title":"Simultaneous determination of pyrazinamide, rifampicin, ethambutol, isoniazid and Acetyl Isoniazid in human plasma by LC-MS\/MS method","volume":"8","author":"Luyen","year":"2018","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.jpba.2023.115650_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122986","article-title":"LC-MS\/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: implications for therapeutic drug monitoring","volume":"1185","author":"Kivrane","year":"2021","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2023.115650_bib29","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/rcm.2961","article-title":"Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography\/tandem mass spectrometry","volume":"21","author":"Song","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2023.115650_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2014.08.026","article-title":"Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography\u2013electrospray ionization\u2013tandem mass spectrometry","volume":"102","author":"Kim","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115650_bib31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jpba.2016.02.013","article-title":"Validation of a simple HPLC-UV method for rifampicin determination in plasma: application to the study of rifampicin arteriovenous concentration gradient","volume":"123","author":"Goutal","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115650_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17425255.2021.1836158","article-title":"Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems","volume":"17","author":"M\u00e4rtson","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jpba.2023.115650_bib33","first-page":"235","article-title":"Rifampin levels in daily practice: the accuracy of a single measurement","volume":"76","author":"Vanbrabant","year":"2018","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.jpba.2023.115650_bib34","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jchromb.2009.04.038","article-title":"Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography\u2013tandem mass spectrometry","volume":"877","author":"de Velde","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2023.115650_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchromb.2007.07.005","article-title":"A rapid and sensitive HPLC\u2013MS method for the detection of plasma and cellular rifampicin","volume":"857","author":"Hartkoorn","year":"2007","journal-title":"J. Chromatogr. B"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523004193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:38:22Z","timestamp":1778542702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523004193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":35,"alternative-id":["S0731708523004193"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115650","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New approach to rifampicin stability and first-line anti-tubercular drug pharmacokinetics by UPLC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115650","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115650"}}